Insulet Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
3,900
- Stock Symbol
-
PODD
- Investments
-
8
- Share Price
-
$297.46
- (As of Wednesday Closing)
Insulet General Information
Description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Contact Information
Website
www.insulet.comCorporate Office
- 100 Nagog Park
- Acton, MA 01720
- United States
Corporate Office
- 100 Nagog Park
- Acton, MA 01720
- United States
Insulet Timeline
Insulet Stock Performance
As of 09-Jul-2025, Insulet’s stock price is $297.46. Its current market cap is $20.9B with 70.4M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $297.46 | $296.51 | $173.00 - $329.33 | $20.9B | 70.4M | 835K | $5.74 |
Insulet Financials Summary
As of 31-Mar-2025, Insulet has a trailing 12-month revenue of $2.2B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 18,880,777 | 18,808,396 | 15,901,797 | 21,130,204 |
| Revenue | 2,198,900 | 2,071,600 | 1,697,100 | 1,305,300 |
| EBITDA | 377,900 | 384,200 | 295,000 | 99,700 |
| Net Income | 402,200 | 418,300 | 206,300 | 4,600 |
| Total Assets | 3,517,300 | 3,087,700 | 2,588,200 | 2,251,100 |
| Total Debt | 1,695,400 | 1,392,100 | 1,415,800 | 1,401,800 |
Insulet Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Insulet Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Insulet Comparisons
Industry
Financing
Details
Insulet Competitors (4)
One of Insulet’s 4 competitors is MannKind, a Formerly VC-backed company based in Westlake Village, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MannKind | Formerly VC-backed | Westlake Village, CA | ||||
| CeQur Simplicity | Venture Capital-Backed | Luzern, Switzerland | ||||
| Haselmeier | Corporate Backed or Acquired | Stuttgart, Germany | ||||
| Enable Injections | Venture Capital-Backed | Cincinnati, OH |
Insulet Patents
Insulet Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250135114-A1 | Co-location cradle for automated medicament delivery systems and analyte sensors and deployment thereof | Pending | 31-Oct-2023 | ||
| EP-4546369-A1 | Automated medicament delivery devices, controllers, and methods for patient protection, management, and communication | Pending | 27-Oct-2023 | ||
| US-20250135121-A1 | Automated medicament delivery devices, controllers, and methods for patient protection, management, and communication | Pending | 27-Oct-2023 | ||
| EP-4546359-A2 | Automated medicament delivery system management without analyte measurements | Pending | 23-Oct-2023 | ||
| US-20250132007-A1 | Automated medicament delivery system management without analyte measurements | Pending | 23-Oct-2023 | G16H20/17 |
Insulet Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Insulet Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Insulet Investments & Acquisitions (8)
Insulet’s most recent deal was a Merger/Acquisition with Automated Glucose Control for . The deal was made on 14-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Automated Glucose Control | 14-Feb-2023 | Merger/Acquisition | Other Devices and Supplies | ||
| Bigfoot Biomedical ( Automated Insulin Delivery Technology Patents) | 13-Feb-2023 | Corporate Asset Purchase | Drug Delivery | ||
| Dynalloy | 03-Jan-2022 | Merger/Acquisition | Other Commercial Products | ||
| Glooko | 16-Mar-2021 | Later Stage VC | Enterprise Systems (Healthcare) | ||
| Glooko | 27-Jun-2017 | Later Stage VC | Enterprise Systems (Healthcare) |
Insulet ESG
Risk Overview
Risk Rating
Updated April, 05, 2025
19.06 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Healthcare
Industry
of 562
Rank
Percentile
Medical Devices
Subindustry
of 194
Rank
Percentile
Insulet Exits (1)
Insulet’s most recent exit was on 01-Jun-2011 from Neighborhood Diabetes. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Neighborhood Diabetes | 01-Jun-2011 | Completed |
|
Insulet Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Dynalloy | Irvine, CA |
Insulet FAQs
-
When was Insulet founded?
Insulet was founded in 2000.
-
Where is Insulet headquartered?
Insulet is headquartered in Acton, MA.
-
What is the size of Insulet?
Insulet has 3,900 total employees.
-
What industry is Insulet in?
Insulet’s primary industry is Drug Delivery.
-
Is Insulet a private or public company?
Insulet is a Public company.
-
What is Insulet’s stock symbol?
The ticker symbol for Insulet is PODD.
-
What is the current stock price of Insulet?
As of 09-Jul-2025 the stock price of Insulet is $297.46.
-
What is the current market cap of Insulet?
The current market capitalization of Insulet is $20.9B.
-
What is Insulet’s current revenue?
The trailing twelve month revenue for Insulet is $2.2B.
-
Who are Insulet’s competitors?
MannKind, CeQur Simplicity, Haselmeier, and Enable Injections are competitors of Insulet.
-
What is Insulet’s annual earnings per share (EPS)?
Insulet’s EPS for 12 months was $5.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
